Zydus Lifesciences Limited has informed the Exchange regarding a press release dated April 25, 2025, titled "Zydus Lifesciences Limited signs purchase agreement with PAI Partners and other shareholders to acquire a majority stake in Amplitude Surgical SA".
ZYDUSLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.9 pts more than Nifty 100 and 3.1 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Zydus Lifesciences has signed a share purchase agreement to acquire 85.6% of French orthopaedic surgical technologies company Amplitude Surgical SA at €6.25 per share. The stake is being bought from private equity firm PAI Partners, Amplitude CEO Olivier Jallabert, and other managers, plus two minority shareholders. Amplitude is a leading French player in lower-limb orthopaedic products (hip and knee), with annual sales of around €106 million and 428 employees as of mid-2024. The deal is subject to French regulatory approvals and is expected to close by Q3 2025, after which Zydus will file a mandatory tender offer with French markets regulator AMF, likely followed by a squeeze-out of remaining shareholders.
This is a significant cross-border acquisition that expands Zydus into the global orthopaedic medical devices market and diversifies its revenue base beyond its core India pharma business. Shareholders should view this positively as a growth-oriented move, though near-term stock impact may be muted until deal closure and financial details emerge.